#
Title
1

Laser Therapies Beyond SLT: July 2026 Protocol Innovations

2

Corneal Biomechanics as a Risk Modifier: Last-Month Evidence

3

Diurnal and Nocturnal Behavior of Episcleral Venous Pressure

4

The Optic Nerve Head Perfusion Equation: Venous Pressure, IOP, and Susceptibility to Damage

5

The IOP Floor: How Episcleral Venous Pressure Limits Trabecular and Canal-Based Glaucoma Procedures

6

Carotid-Cavernous Fistula and Glaucoma: Venous Hypertension at the Eye

7

Glutathione-centered strategies: NAC vs GlyNAC vs dietary sulfur donors

8

Week 2 After Trabeculectomy: Transitioning to Light Chores and Remote Work

9

Days 5–7 After Trabeculectomy: Completing Week One With Safer Routines and Visual Comfort

10

Days 3–4 After Trabeculectomy: Calming Inflammation While Staying Mobile

11

How Does the PreserFlo MicroShunt Stack Up Against Trabeculectomy and Other Drainage Devices?

12

Lowering Eye Pressure: The Lumigan vs Roclanda Showdown

13

Glaucoma Drainage Implants in Midlife: Decoding the Long-Term Success Rates

14

The Hidden Eye Risk in Athletes: Understanding Pigment Dispersion Syndrome and Pigmentary Glaucoma

15

Patient‑Reported Outcomes and Quality of Life After Glaucoma Procedures

16

The Glaucoma Shunt Journey: What to Expect Before, During, and After Surgery

17

Targeting Very Low IOPs: Achieving Single‑Digit Pressures Safely

18

SLT’s Evolving Role Relative to MIGS and Surgery

19

Trabeculectomy vs Tube Shunts in the Modern Era: Long-Term Safety and Durability

20

Do Orally Ingested Collagen Peptides Reach the Eye

21

Collagen Peptides and the Trabecular Meshwork: Mechanistic Links to Intraocular Pressure

22

Can Ferroptosis Supplements Protect Vision in Glaucoma? What the New Dnajb14 Discovery Really Means

23

Is Glaucoma an Energy Failure Disease? Mitochondria, Aging, and the Optic Nerve

24

The Future of Glaucoma Care May Be Personal: Matching Treatment to Each Patient’s Risk

25

Can the Optic Nerve Be Protected? The New Neuroprotection Era in Glaucoma Research

26

Sustained-release glaucoma implants

27

Disease-modifying glaucoma drugs

28

The Copper Peptide and the Optic Nerve: A Deep Look at GHK-Cu, Oxidative Stress, and Glaucoma

29

Brain Imaging Biomarkers and Plasticity in Glaucoma

30

Glaucoma and Glutamine: Is There a Real Link Through Glutamate, Retinal Metabolism, and Neurodegeneration?

31

Nocturnal hypotension, sleep apnea, and ocular perfusion: continuous monitoring studies

32

Economics of high-frequency home monitoring versus clinic-based perimetry

33

Color and contrast-specific perimetry to probe retinal ganglion cell subtype vulnerability

34

Inequities in access to visual field testing and their outcome consequences

35

Low-Carb Diets and Nocturnal Blood Pressure Dips: Ocular Perfusion Risks and Benefits

36

Macronutrient Patterns and Intraocular Pressure: A Systematic Evaluation

37

Personalized Nutrition in Glaucoma: Nutrigenomic Interactions with Macronutrient Metabolism

38

Medium-Chain Triglycerides vs Long-Chain Fats: Rapid Ketosis and Visual Function

39

Protein Intake, Homocysteine, and Pseudoexfoliation Glaucoma Risk

40

mTOR/Autophagy Modulation by Amino Acids in RGC Degeneration

41

NR vs NMN vs Nicotinamide for Glaucoma: Which NAD+ Booster Has the Strongest Evidence?

42

How Useful Is OCT at Each Stage of Glaucoma?

43

New Glaucoma Treatments in 2026: What Patients Should Know About Longer-Lasting Eye Pressure Control

44

Endothelin-1 Peptide and Glaucoma: Targeting a Problem Pathway

45

Substance P, Pain, and Neuroinflammation in Glaucoma

46

GLP-1 Peptides and Glaucoma Risk: What We Know and What to Watch

47

Nerve Growth Factor–Based Peptides and Optic Nerve Protection

48

Heat shock protein-derived peptides and autoimmunity in glaucoma

49

Endothelin pathway peptides and optic nerve head ischemia in glaucoma

50

MOTS-c and Glaucoma: A Mitochondrial Signal With Bigger Implications Than Eye Pressure?

51

Senolytics and the Glaucoma Niche: Clearing Old Cells for Longer-Life Signals

52

Ketogenic Signals and Beta-Hydroxybutyrate: IOP, Neuroprotection, and Longevity Intersections

53

The Glaucoma Energy Crisis: How Pyruvate Rescues Failing Eyes (And Why Your Fitness Level Matters)

54

Photobiomodulation (670 nm) for Aging Retina: Lifespan Signals from Flies to Mammals

55

What’s New in Glaucoma Research in April 2026? What Patients Should Know

56

A New Clue in Glaucoma: Leaky Blood Vessels May Damage Vision

57

April 2026 Glaucoma Trial Launches: A Global Landscape Review

58

April 2026 Glaucoma Trial Launches: A Global Landscape Review

59

Therapeutic Mechanisms Debuting in April 2026 Glaucoma Trials

60

Gene- and Cell-Based Therapies Entering Glaucoma Trials in April 2026

61

Home Tonometers and Contact Lens Sensors in April 2026 Protocols

62

Washout and Rescue Protocols in April 2026 IOP-Lowering Studies

63

Hyperbaric Oxygen Therapy and Glaucoma: Mechanistic Rationale and Biological Plausibility

64

Oxidative Stress, Hormesis, and the Hyperoxia Paradox in Glaucoma

65

Soccer and Glaucoma: Endurance Gains Amid Collision Risks

66

Hiking and Glaucoma: Terrain, Altitude, and Sun Exposure

67

Running and Jogging with Glaucoma: Balancing Cardiovascular Gains and IOP Fluctuations

68

Road Cycling and Glaucoma: Aerobic Advantage with Posture and Safety Considerations

69

Snorkeling and Glaucoma: Gentle Aquatic Activity with Mask and Sunlight Considerations

70

SCUBA Diving and Glaucoma: Pressure, Perfusion, and Post-Surgical Precautions

71

Lap Swimming and Glaucoma: Cardiorespiratory Benefits vs. Goggle and Head Position Issues

72

Basketball and Glaucoma: Dynamic Cardio with Contact and Glare Considerations

73

General Resistance Training and Glaucoma: Building Strength While Managing IOP Spikes

74

High-Intensity Interval Training (HIIT) and Glaucoma: Short Bouts, Big Questions

75

Can Eye Blood Vessel Changes Warn of Future Glaucoma Damage Before Vision Tests Turn Abnormal?

76

Does Angle-Closure Risk Build Up Earlier in Life Than People Think?

77

Can Exercise, Better Sleep, and Stress Reduction Help in Glaucoma? What a New March 2026 Study Suggests

78

If One Person in the Family Has Glaucoma, Should Everyone Else Get Checked?

79

A New Glaucoma Drug Study Is Starting: Could an Oral Cannabinoid Help Lower Eye Pressure?

80

What Was Actually New in Glaucoma This Month? A Plain-English Guide to the Most Important March 2026 Updates

81

Why Is It So Hard to Prove a Treatment Protects the Optic Nerve in Glaucoma?

82

A New Way to Read Eye Scans in Glaucoma: Can 3D Nerve Fiber Shape Improve Detection?

83

Could Better Scan Databases Help Catch Glaucoma Earlier? What a New March 2026 Study Found

84

Does Eye Pressure Damage Show Up Before Vision Gets Worse? A New March 2026 Glaucoma Study Explains the Time Lag

85

A Cataract Lens That Also Treats Glaucoma? What the New BIM-IOL Study Means for Patients

86

Why Vision Restoration Is So Much Harder in Glaucoma Than in Some Other Eye Diseases

87

Eyes Wide Open: How Karpathy's Autoresearch Framework Could Democratize Glaucoma Research — A Blueprint for Patient-Led, AI-Driven Discovery in Vision Restoration

88

Can a Light-Sensing Drug Help Restore Vision? Understanding the Newest KIO-301 Research

89

A Treatment That Helped Some Blind Patients See More Light and Shape: What MCO-010 Means for Vision Restoration

90

Helping New Cells Survive: How Tiny Drug Carriers May Support Future Vision Repair in Glaucoma

91

Could Cell Transplants One Day Restore Vision in Glaucoma? A New Study Looks at One Major Roadblock

92

A New Glaucoma Implant Study: Can It Protect Vision, and Can It Bring Lost Vision Back?

93

What Is a 24-2 Visual Field Test

94

How Fast Does Glaucoma Progress

95

Perioperative Pitfalls: Supplements That Raise Bleeding Risk in Glaucoma Surgery

96

Does Diabetes Cause Glaucoma

97

Can You Have Glaucoma in One Eye

98

Zinc, Copper, and Optic Neuropathy: When Supplements Mimic Glaucoma Progression

99

How Long Does a Glaucoma Test Take

100

Which Is Worse Cataracts or Glaucoma

101

Does Glaucoma Cause Headaches

102

How to Test for Glaucoma

103

Is Glaucoma a Disability

104

Is Glaucoma Genetic

105

What Is Narrow Angle Glaucoma

106

What Are the Symptoms of Glaucoma

107

How to Prevent Glaucoma

108

What Does Glaucoma Look Like

109

What Causes Glaucoma

110

Magnesium and Glaucoma: A Systematic Review of Human Evidence

111

Antioxidant Vitamins and Minerals: Do A, C, E, Zinc, and Selenium Matter in Glaucoma?

112

Sodium, Blood Pressure, and Ocular Perfusion: Dietary Salt in Glaucoma Care

113

Soy Foods, Phytoestrogens, and Glaucoma in Women

114

Lifestyle Levers to Extend Visual Healthspan

115

Blue Zones and Centenarians: Ocular Phenotypes of Exceptional Agers

116

Metformin, Rapamycin, and Geroscience Drugs: Ocular Outcomes

117

ER-100 Clinical Trial for Glaucoma: What We Know So Far and What to Expect

118

Glaucoma Eye Drops, Dry Eye, and Sleep Quality: Exploring Hidden Connections and What Patients Can Do

119

The Ocular Microbiome, Inflammaging, and Surface Health

120

Methods of Visual Field Testing in Glaucoma: How They Differ and What Each Reveals

121

The Limitations of Visual Field Testing in Glaucoma: Frequency, Subjectivity, and What Gets Missed

122

Home Tonometry and Remote Monitoring in Glaucoma – A Patient-Centered Investigation

123

Predicting Glaucoma Before It Starts: How Close Are We to Genetic Risk Scores That Actually Change Patient Outcomes?

124

Glaucoma Clinical Trials Launched in 2025: A Complete Overview

125

Patterns of Vision Loss in Glaucoma: Large Blind Spots Versus Scattered Missing Points

126

How Fast Is AI Actually Progressing, and What Does It Mean for Glaucoma Patients and Researchers?

127

AI in Glaucoma: What's Working Now, What's Coming Next, and Where the Real Opportunities Lie

128

Glaucoma Vision Restoration: What's New in January 2026

129

Hydrogen Water Research Compiled: Studies, Dosages, Applications, and Outcomes

130

Pyruvate Supplementation for Glaucoma: Comparing Forms, Efficacy, and Global Availability

131

Nitric Oxide Pathway Supplements (L-Arginine, L-Citrulline) and Aqueous Outflow

132

Pyrroloquinoline Quinone (PQQ) and Mitochondrial Biogenesis in RGCs

133

Myopia and Glaucoma: When Nearsightedness Raises the Stakes

134

HDL cholesterol and apolipoprotein A-I: protective or paradoxical in glaucoma?

135

Complement proteins C3 and C4: systemic innate immunity and glaucoma progression

136

Systemic immune-inflammation index (SII) and the speed of RNFL loss

137

Coagulation markers (fibrinogen and D-dimer) and optic nerve microthrombosis

138

Redox Balance and Glaucoma: Is More Antioxidants Always Better for Your Eyes?

139

Red cell distribution width as a microvascular stress marker in glaucoma

140

Beyond the Marketing: Which Hydrogen Water Bottles Have Verified Test Results?

141

Hydrogen Water Buying Guide for Glaucoma-Focused Consumers: Science-First Approach

142

High-Sensitivity CRP: Systemic Inflammation and Glaucoma Neurodegeneration

143

ApoB, ApoA1, and Non-HDL Cholesterol: Refining Atherogenic Risk in Glaucoma Patients

144

Platelet Metrics (Mean Platelet Volume) and Microvascular Risk in Glaucoma

145

Uric Acid: Antioxidant Versus Pro-oxidant in Glaucoma

146

IGF-1, mTOR Signaling, and Neurodegeneration Across Eye and Brain

147

Oxidative Stress Biomarkers, HRV, and Retinal Ganglion Cell Loss

148

Stacking Blood-Thinning Supplements: Cumulative Bleeding Risk in Glaucoma Patients

149

Selective Laser Trabeculoplasty in the Era of OTC Blood Thinners: Hyphema and IOP Spikes

150

SLT as First-Line Therapy: Who Benefits and When to Repeat

151

Neuroprotection Beyond Pressure: What’s Real, What’s Hype

152

Dry Eye Can Fake Progression: Fix the Surface, Fix the Tests

153

Contact Lenses With Glaucoma: Timing Drops, Preservatives, and Comfort

154

Adherence That Sticks: Storage, Travel, and Tech Tools for Glaucoma Drops

155

Vasospasm, Cold Hands, and Normal-Tension Glaucoma: The Raynaud’s Connection

156

Exercise Smart: Aerobic vs Weightlifting, Valsalva, and Yoga Inversions

157

Sleep Posture Hacks: Head Elevation and Side-Sleeping Effects on Eye Pressure

158

The Nighttime Blood Pressure Dip: A Hidden Driver in Normal-Tension Glaucoma

159

Measuring What Matters: Beyond Visual Fields to Functional Vision

160

Hydration Habits: Water-Drinking Spikes and How to Sip Safely

161

Mastering Eye Drop Technique: Nasolacrimal Occlusion to Boost Efficacy and Safety

162

Vitamins C and E in Glaucoma: Antioxidants Revisited

163

Mirtogenol (Pycnogenol + Bilberry) and Eye Pressure: A Critical Appraisal

164

Caffeine, Coffee, and Tea: How Do They Impact Eye Pressure?

165

Palmitoylethanolamide (PEA) as an Adjunct in Glaucoma

166

Can Restoring Ocular Perfusion Restore Vision? OCT-A and Vascular Therapies

167

Cortical Plasticity and Perceptual Learning: Can the Brain Compensate for Optic Nerve Damage?

168

ROCK Inhibitors Beyond IOP: Axonal Regrowth, Perfusion, and Neuroprotection

169

Brain Stimulation for Glaucoma: tDCS, TMS, and Visual Cortex Modulation

170

Circadian Biology, ipRGCs, and Neuroprotection in Glaucoma

171

The 2024–2025 Pipeline for IOP-Independent Neuroprotection in Glaucoma

172

Forecasting Glaucoma Vision Restoration: 5-, 10-, and 20-Year Outlook

173

Nicotinamide and Mitochondrial Rescue: Can Metabolic Therapy Restore Function?

174

Artificial Vision for End-Stage Glaucoma: Retinal vs. Cortical Prostheses

175

Stem Cell–Derived RGC Transplantation: From Petri Dish to Optic Tract

176

Electrical Stimulation for Glaucoma: Signal Boost or True Neurorestoration?

177

Gene Therapy for Optic Nerve Regeneration: Modulating PTEN/mTOR, KLFs, and Sox11

178

Quercetin and Fisetin as Candidate Senolytics in Optic Nerve Aging

179

Citrus Bioflavonoids (Hesperidin, Diosmin) for Ocular Hemodynamics

180

Molecular Hydrogen and Redox Signaling in Ocular Neuroprotection

181

Anthocyanins and Bilberry Extracts: Retinal Resilience and Aging Microvasculature

182

Taurine and Retinal Ganglion Cell Survival Across the Lifespan

183

Green Tea Catechins (EGCG) for Neurovascular Health in Glaucoma and Aging

184

Melatonin, Circadian Rhythms, and Nocturnal IOP Dynamics

185

The Gut–Eye Axis: Probiotics, Metabolites, and Intraocular Pressure

186

Magnesium for Vascular Dysregulation in Glaucoma and Aging Circulation

187

Resveratrol and Sirtuin Pathways: From Trabecular Meshwork to Longevity

188

Macular Carotenoids (Lutein, Zeaxanthin, Meso-zeaxanthin) Beyond the Macula

189

Saffron (Crocins) in Optic Neuroprotection: Translating Retinal Evidence to Glaucoma

190

Safety, Interactions, and Regulatory Oversight of Glaucoma Supplements

191

Spermidine and Autophagy: A Longevity Nutrient for the Aging Eye

192

Curcumin and Curcuminoids: Anti-inflammatory Strategies for Glaucoma Neuroprotection

193

Vitamin D Status, Intraocular Pressure, and Neuroinflammation

194

N-Acetylcysteine and Glutathione: Fortifying Antioxidant Defenses in the Aging Eye

195

From Bench to Bedside: Translating Longevity Pathways to Glaucoma Supplements

196

Omega-3 Fatty Acids, Inflammation Resolution, and Glaucoma Progression

197

Citicoline (CDP-Choline) for Visual Pathway Support and Cognitive Aging

198

Alpha-Lipoic Acid: Redox Modulation and Neurovascular Support in Glaucoma

199

Creatine and Energy Buffering in Retinal and Optic Nerve Tissues

200

Astaxanthin for Oxidative Stress and Ocular Blood Flow

201

Designing Multi-Ingredient Neuroprotective Formulations for Glaucoma

202

B Vitamins, Homocysteine, and Vascular Dysregulation in Glaucoma

203

Ginkgo biloba for Ocular Perfusion and Visual Field Preservation: Promise and Precautions

204

Coenzyme Q10 as a Mitochondrial Adjunct in Glaucoma and Lifespan Health

205

Tele-Glaucoma and Home Monitoring in Aging Populations

206

Nicotinamide and NAD+ Boosting for Glaucoma Neuroprotection and Healthy Aging